1. 2022-RA-324-ESGO Phase 2 results from the LIO-1 STUDY (NCT04042116; ENGOT-GYN3/AGO/LIO): efficacy and safety of lucitanib + nivolumab in patients with advanced gynaecological malignancies. (20th October 2022) Authors: Concin, Nicole; Patel, Manish R; Makker, Vicky; Oaknin, Ana; Pignata, Sandro; Backes, Floor J; González-Martín, Antonio; Eskander, Ramez N; Pothuri, Bhavana; Richardson, Debra L; Secord, Angeles Alvarez; van Nieuwenhuysen, Els; Liu, Joyce F; Musa, Fernanda; Penson, Richard T; Wride, Kenton; Dusek... Journal: International journal of gynecological cancer Issue: Volume 32(2022)Supplement 2 Page Start: A185 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 313 A phase 1 evaluation of tebotelimab, a bispecific PD-1 x LAG-3 DART® molecule, in combination with margetuximab in patients with advanced HER2+ neoplasms. (9th November 2020) Authors: Patel, Manish; Luke, Jason; Hamilton, Erika; Chmielowski, Bartosz; Blumenschein, George; Kindler, Hedy; Bahadur, Shakeela; Santa-Maria, Cesar; Koucheki, Janine; Sun, Jichao; Kaul, Sanjeev; Chen, Francine; Zhang, Xiaoyu; Muth, John; Kaminker, Patrick; Moore, Paul; Sumrow, Bradley; Ulahannan, Susanna Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A193 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 313 A phase 1 evaluation of tebotelimab, a bispecific PD-1 x LAG-3 DART® molecule, in combination with margetuximab in patients with advanced HER2+ neoplasms. (9th November 2020) Authors: Patel, Manish; Luke, Jason; Hamilton, Erika; Chmielowski, Bartosz; Blumenschein, George; Kindler, Hedy; Bahadur, Shakeela; Santa-Maria, Cesar; Koucheki, Janine; Sun, Jichao; Kaul, Sanjeev; Chen, Francine; Zhang, Xiaoyu; Muth, John; Kaminker, Patrick; Moore, Paul; Sumrow, Bradley; Ulahannan, Susanna Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A340 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 317 A phase 1/1b study of SBT6050, a HER2-directed monoclonal antibody conjugated to a toll-like receptor 8 agonist, in subjects with advanced HER2-expressing solid tumors. (9th November 2020) Authors: Emens, Leisha; Beeram, Muralidhar; Hamilton, Erika; Piha-Paul, Sarina; Odegard, Valerie; Hamke, Sue; Hunder, Naomi; Klempner, Samuel Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A195 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. 317 A phase 1/1b study of SBT6050, a HER2-directed monoclonal antibody conjugated to a toll-like receptor 8 agonist, in subjects with advanced HER2-expressing solid tumors. (9th November 2020) Authors: Emens, Leisha; Beeram, Muralidhar; Hamilton, Erika; Piha-Paul, Sarina; Odegard, Valerie; Hamke, Sue; Hunder, Naomi; Klempner, Samuel Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A343 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. 801 PRIME™ IL-15 (RPTR-147): Preliminary clinical results and biomarker analysis from a first-in-human Phase 1 study of IL-15 loaded peripherally-derived autologous T cell therapy in solid tumor patients. (9th November 2020) Authors: Hamilton, Erika; Nikiforow, Sarah; Bardwell, Philip; McInnis, Christine; Zhang, Jeffrey; Blumenschein, George; Cristea, Mihaela; Osman, Keren; Shields, Anthony; Motta, Marlyane; Bilic, Sanela; Schoenborn-Kellenberger, Oliver; Rakestraw, James; Carey, Shawn; Geretti, Elena; Sauer, Karsten; Harris,... Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A850 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Antibody-drug conjugates targeting TROP-2: Clinical development in metastatic breast cancer. (December 2022) Authors: Shastry, Mythili; Jacob, Saya; Rugo, Hope S.; Hamilton, Erika Journal: Breast Issue: Volume 66(2022) Page Start: 169 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Efficacy, safety and toxicity management of adjuvant abemaciclib in early stage HR+/HER2- high-risk breast cancer. Issue 8 (3rd August 2022) Authors: Sammons, Sarah; Moore, Heather; Cushman, Jaycee; Hamilton, Erika Journal: Expert review of anticancer therapy Issue: Volume 22:Issue 8(2022) Page Start: 805 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. EP017/#425 Comparison of NAPI2B expression from paired tissue samples in a clinical study of upifitamab rilsodotin (UPRI; XMT-1536) supports a strategy of testing in archive material. (4th December 2022) Authors: Richardson, Debra; Barve, Minal; Saltos, Andreas; Papadopoulos, Kyriakos; Hays, John; Tolcher, Anthony; Ellard, Susan; Doroshow, Deborah; Mitchell, Paul; Zarwan, Corrine; Werner, Theresa; Anderson, Charles; Spira, Alex; Mileshkin, Linda; Bradshaw, Chelsea; Demars, Leslie; Mosher, Rebecca; Hamilto... Journal: International journal of gynecological cancer Issue: Volume 32(2022)Supplement 3 Page Start: A55 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. First‐in‐human, phase I study of PF‐06647263, an anti‐EFNA4 calicheamicin antibody–drug conjugate, in patients with advanced solid tumors. Issue 7 (23rd February 2019) Authors: Garrido‐Laguna, Ignacio; Krop, Ian; Burris, Howard A.; Hamilton, Erika; Braiteh, Fadi; Weise, Amy M.; Abu‐Khalaf, Maysa; Werner, Theresa L.; Pirie‐Shepherd, Steven; Zopf, Christopher J.; Lakshminarayanan, Mani; Holland, Jaymes S.; Baffa, Raffaele; Hong, David S. Journal: International journal of cancer Issue: Volume 145:Issue 7(2019) Page Start: 1798 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗